Clinical Trial Update: Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial investigating cytochrome P450 inhibition to reduce dasatinib dosage in chronic myeloid leukemia (chronic phase).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Chronic Phase

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Status: UNKNOWN